Ramucirumab in Indian Patients with Advanced Gastric Cancer—Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?

Background  Ramucirumab is considered a standard of care as second-line therapy (CT2) in advanced gastric cancers (AGCs). The aim of this study was to assess practice patterns and outcomes with ramucirumab among Indian patients with AGCs. Materials and Methods  A computerized clinical data entry for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaswamy, Anant, Bajaj, Kripa, Talwar, Vineet, Prabhash, Kumar, Batra, Ullas, Dhabhar, Boman, Sharma, Mansi, Ghadyalpatil, Nikhil, CT, Satish, Goyal, Gautam, Muzamil, Javvid, Bhatt, Amit, Jain, Parveen, Ranade, Anantbhushan, Kamath, Mangesh, Gawande, Jayant Pundlik, Thippeswamy, Ravi, Mirani, Jimmy, Reddy, Neelesh, Ganguly, Sandip, Mishra, Sourav Kumar, Madabhavi, Irappa, HP, Shashidhara, Panda, Soumya Surath, Patil, Shekar, Bhargava, Prabhat, Ostwal, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273313/
https://www.ncbi.nlm.nih.gov/pubmed/35833042
http://dx.doi.org/10.1055/s-0041-1728980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273313/
https://www.ncbi.nlm.nih.gov/pubmed/35833042
http://dx.doi.org/10.1055/s-0041-1728980

Ejemplares similares